Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-21-008389
Filing Date
2021-02-11
Accepted
2021-02-11 13:29:52
Documents
1
Period of Report
2021-02-05

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 5763
  Complete submission text file 0001213900-21-008389.txt   7216
Mailing Address C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE, 4TH FLOOR CAMBRIDGE MA 02139
Business Address
Rhodes Jason P (Reporting) CIK: 0001577014 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39438 | Film No.: 21618396

Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Issuer) CIK: 0001816736 (see all company filings)

EIN.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations